Neoadjuvant treatment before radical prostatectomy: Current situation скачать в хорошем качестве

Neoadjuvant treatment before radical prostatectomy: Current situation

Prof Nicolas Mottet speaks to ecancer at the 2019 International Gastrointestinal, Liver and Uro-Oncology Conference (IGILUC) in Cairo about the neoadjuvant treatment prior to surgery in patients with prostate cancer. Prof Mottet describes the types of neoadjuvant therapy which consists of either oral treatment or a combination of oral treatment plus chemotherapy. The use of bicalutamide as an oral therapy has shown little added value, however newer drugs such as enzalutamide and abiraterone have shown limited data thus far. In regard to the combination of docetaxel and ADT along with local treatment, Prof Mottet notes one French trial which achieved an improvement in progression-free survival, however this did not translate with metastasis-free or overall survival. Prof Mottet also emphasises that this data is purely experimental at this stage and that neoadjuvant ADT should not be used prior to surgery - as stated in the recommended guidelines. Sign up to ecancer for free to receive tailored email alerts for more videos like this. ecancer.org/account/register.php